Clinical Trials
3 trialsNCT03604198 2026-04-21
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Corcept Therapeutics
Phase 2 Active not recruiting
NCT05307328 2025-10-08
RESCUE
Sparrow Pharmaceuticals
Phase 2 Completed
NCT05971758 2025-07-04
Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease
University of California, Los Angeles
Phase 2 Recruiting